
zzso was given to 25 patients with advanced cancer on a twice weekly schedule in escalating doses from 165 to zzso zzso zzso zzso fatigue, generalized zzso and decreases in performance status were zzso In one patient treated at a dose of zzso zzso for three doses, zzso anemia resulted, with a zzso decrease in zzso No tumor zzso zzso A reasonable starting dose for phase II studies is 1200 zzso twice weekly for 3 weeks, with planned rapid escalation to zzso zzso in patients tolerating the lower dose zzso 

